Should separate endpoint trials be required for all lipid-lowering drugs acting by the same mechanism?
作者信息
Shepherd J, Olsson A G, Sacks F M, Black D M, Orloff D G, Bilheimer D W
机构信息
Department of Pathological Biochemistry, Royal Infirmary, Glasgow, Scotland.
出版信息
Am J Cardiol. 1998 Apr 23;81(8A):88F-94F.
PMID:9604922
Abstract
摘要
相似文献
1
Should separate endpoint trials be required for all lipid-lowering drugs acting by the same mechanism?
Am J Cardiol. 1998 Apr 23;81(8A):88F-94F.
2
What kinds of studies should be required to probe efficacy and safety of drugs in special populations?需要开展哪些类型的研究来探究药物在特殊人群中的疗效和安全性？
Am J Cardiol. 1998 Apr 23;81(8A):84F-87F.
3
[Lipid distress syndrome in atherosclerosis obliterans].
Vestn Ross Akad Med Nauk. 1999(9):28-31.
4
Recommendations for Phase IV studies in the development of lipid-lowering drugs.降脂药物研发中IV期研究的建议。
Am J Cardiol. 1998 Apr 23;81(8A):64F-66F. doi: 10.1016/s0002-9149(98)00267-7.
5
Requirements and methods for documenting diet uniformity and compliance in drug development trials.
Am J Cardiol. 1998 Apr 23;81(8A):31F-33F. doi: 10.1016/s0002-9149(98)00257-4.
6
Regression of computer estimated femoral atherosclerosis after pronounced serum lipid lowering in patients with asymptomatic hyperlipidaemia.
Lancet. 1982 Jun 5;1(8284):1311. doi: 10.1016/s0140-6736(82)92881-1.
7
Early efficacy and safety studies.
Am J Cardiol. 1998 Apr 23;81(8A):13F-16F. doi: 10.1016/s0002-9149(98)00252-5.
8
[KLAS [Kanazawa Lipid Assessment Survey]].
Nihon Rinsho. 2001 Mar;59 Suppl 3:469-76.
9
Therapy and clinical trials.治疗与临床试验。
Curr Opin Lipidol. 1996 Oct;7(5):U168-72. doi: 10.1097/00041433-199610000-00020.
10
Clinical trial assessment of lipid-acting drugs in diabetic patients.
Am J Cardiol. 1998 Apr 23;81(8A):58F-59F. doi: 10.1016/s0002-9149(98)00265-3.
Zotero 插件